Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Introduction: An Evidence-Based Approach for Prevention and Management of Surgical Complications hoofdstuk lezen eerste hoofdstuk lezen

2014 | OriginalPaper | Hoofdstuk

14. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)

Auteurs : Samantha Pozzi, MD, Alexandre Anesi, MD, Luigi Generali, MD, Alessia Bari, MD, Ugo Consolo, MD, Luigi Chiarini, MD

Gepubliceerd in: Complications in Endodontic Surgery

Uitgeverij: Springer Berlin Heidelberg

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Osteonecrosis of the jaw (ONJ) is a rare condition that has been mainly related to the treatment with i.v. bisphosphonates in patients affected by cancer bone disease. The ethiopathology is still unknown and the frequency is between 0.8 and 12 %. It can appear in edentulous patients, but invasive procedures have been demonstrated to increase the risk of developing this complication. Few cases have been described in the endodontic literature. In the next chapter, we will describe ONJ, will analyze the data from literature, and will report expert opinions and guidelines about the best clinical practice in the endodontic field. Finally, since data in this field are limited, we would like to underline that the best treatment plan for cancer patients receiving bisphosphonates and requiring dental procedures is a multidisciplinary, case-by-case approach.
vorige hoofdstuk Nerve Injury During Endodontic Surgical Procedures
volgende hoofdstuk Medicolegal Consideration in Endodontics: General and Surgical Aspects
Literatuur
1.
Brotons A, Penarrocha M. Orofacial neurogenic pain and maxillofacial ischemic osteonecrosis. A review. Med Oral. 2003;8(3):157–65.PubMed
2.
Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg. 1983;41(5): 283–8.PubMedCrossRef
3.
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7.PubMedCrossRef
4.
Ruggiero SL, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–34.PubMedCrossRef
5.
Migliorati CA, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005;104(1):83–93.PubMedCrossRef
6.
Shlomi B, et al. Avascular necrosis of the jaw bone after bisphosphonate therapy. Harefuah. 2005;144(8): 536–9, 600, 599.PubMed
7.
Vannucchi AM, et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol. 2005;128(6):738.PubMedCrossRef
8.
Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005;182(8):417–8.PubMed
9.
Bagan JV, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2006;42(3):327–9.PubMedCrossRef
10.
Raje N, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14(8):2387–95.PubMedCrossRef
11.
Lazarovici TS, et al. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg. 2009;67(4):850–5.PubMedCrossRef
12.
Ruggiero SL. Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin Cases Miner Bone Metab. 2007;4(1):37–42.PubMedCentralPubMed
13.
14.
Rogers MJ, et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49(1): 34–41.PubMedCrossRef
15.
16.
Ruggiero SL, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw – 2009 update. Aust Endod J. 2009;35(3):119–30.PubMedCrossRef
17.
Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, A.A.o.O. and S. Maxillofacial. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369–76.CrossRef
18.
Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg. 2009;67(12):2698–9.PubMedCrossRef
19.
Bedogni A, et al. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis. 2012;18(6):621–3.PubMedCentralPubMedCrossRef
20.
Troeltzsch M, et al. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc. 2012;78:c85.PubMed
21.
Sivolella S, et al. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res. 2013;33(5):1793–7.PubMed
22.
Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353(1):99–102; discussion 99–102.PubMedCrossRef
23.
Bamias A, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23(34):8580–7.PubMedCrossRef
24.
Dimopoulos MA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91(7):968–71.PubMed
25.
Pozzi S, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma. 2007;48(1):56–64.PubMedCrossRef
26.
Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg. 2006;64(6):917–23.PubMedCrossRef
27.
Wang EP, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65(7):1328–31.PubMedCrossRef
28.
Cafro AM, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma. 2008;8(2):111–6.PubMedCrossRef
29.
Hoff AO, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23(6):826–36.PubMedCrossRef
30.
Borromeo GL, et al. A review of the clinical implications of bisphosphonates in dentistry. Aust Dent J. 2011;56(1):2–9.PubMedCrossRef
31.
Mavrokokki T, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65(3):415–23.PubMedCrossRef
32.
McLeod NM, et al. Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg. 2011;49(5):335–42.PubMedCrossRef
33.
Hsiao A, Glickman G, He J. A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates. J Endod. 2009;35(11):1525–8.PubMedCrossRef
34.
Gallego L, et al. Rubber dam clamp trauma during endodontic treatment: a risk factor of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg. 2011;69(6):e93–5.PubMedCrossRef
35.
Goodell G. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Mass Dent Soc. 2006;55(1):44–8.PubMed
36.
Sarathy AP, Bourgeois Jr SL, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod. 2005;31(10):759–63.PubMedCrossRef
37.
Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod. 2005;31(11):831–4.PubMedCrossRef
38.
Campisi G, et al. BRONJ expert panel recommendation of the Italian Societies for Maxillofacial Surgery (SICMF) and Oral Pathology and Medicine (SIPMO) on Bisphosphonate-Related Osteonecrosis of the Jaws: risk assessment, preventive strategies and dental management. It J Maxillofac Surg. 2011;22(2):103–24.
39.
Sedghizadeh PP, et al. Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(2):224–32.PubMedCentralPubMedCrossRef
40.
Terpos E, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network. Ann Oncol. 2009;20(8):1303–17.PubMedCrossRef
41.
Van Poznak CH, Von Roenn JH, Temin S. American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract. 2011;7(2):117–21.PubMedCentralPubMedCrossRef
42.
43.
Marx RE, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63(11):1567–75.PubMedCrossRef
44.
Statement, A.A.o.E.P. Endodontic implications of bisphosphonate-associated Osteonecrosis of the jaws. 2010;1–4.
45.
Siqueira Jr JF. Aetiology of root canal treatment failure: why well-treated teeth can fail. Int Endod J. 2001;34(1):1–10.PubMedCrossRef
46.
Nair PN, et al. Intraradicular bacteria and fungi in root-filled, asymptomatic human teeth with therapy-resistant periapical lesions: a long-term light and electron microscopic follow-up study. J Endod. 1990;16(12):580–8.PubMedCrossRef
47.
Friedman S, Abitbol S, Lawrence HP. Treatment outcome in endodontics: the Toronto Study. Phase 1: initial treatment. J Endod. 2003;29(12):787–93.PubMedCrossRef
48.
Gutmann JL, Harrison JW. Posterior endodontic surgery: anatomical considerations and clinical techniques. Int Endod J. 1985;18(1):8–34.PubMedCrossRef
49.
Song M, Shin SJ, Kim E. Outcomes of endodontic micro-resurgery: a prospective clinical study. J Endod. 2011;37(3):316–20.PubMedCrossRef
50.
Tsesis I, et al. Outcomes of surgical endodontic treatment performed by a modern technique: an updated meta-analysis of the literature. J Endod. 2013;39(3):332–9.PubMedCrossRef
51.
Moinzadeh AT, et al. Bisphosphonates and their clinical implications in endodontic therapy. Int Endod J. 2013;46(5):391–8.PubMedCrossRef
52.
Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2012;12(3 Suppl):233–47.PubMedCrossRef
53.
Kalra S, Jain V. Dental complications and management of patients on bisphosphonate therapy: a review article. J Oral Biol Craniofac Res. 2013;3(1):25–30.CrossRef
54.
Hellstein JW, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142(11):1243–51.PubMedCrossRef
55.
Fantasia JE. Bisphosphonates – what the dentist needs to know: practical considerations. J Oral Maxillofac Surg. 2009;67(5 Suppl):53–60.PubMedCrossRef
56.
Bedogni A, et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(3):358–64.PubMedCrossRef
57.
Hutchinson M, et al. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg. 2010;68(9):2232–40.PubMedCrossRef
58.
O’Ryan FS, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009;67(7): 1363–72.PubMedCrossRef
59.
Wilde F, et al. Prevalence of cone beam computed tomography imaging findings according to the clinical stage of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(6):804–11.PubMedCrossRef
60.
Khosla S, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–91.PubMedCrossRef
61.
American Dental Association Council on Scientific, A. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137(8):1144–50.CrossRef
62.
Migliorati CA, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136(12):1658–68.PubMedCrossRef
63.
Kuhl S, et al. Bisphosphonate-related osteonecrosis of the jaws–a review. Oral Oncol. 2012;48(10):938–47.PubMedCrossRef
64.
Van den Wyngaert T, et al. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2009;20(2):331–6.PubMedCrossRef
65.
Thumbigere-Math V, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009;67(9):1904–13.PubMedCrossRef
66.
Bedogni A, et al. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral Oncol. 2011;47(5):420–4.PubMedCrossRef
67.
Metagegevens
Titel
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)
Auteurs
Samantha Pozzi, MD
Alexandre Anesi, MD
Luigi Generali, MD
Alessia Bari, MD
Ugo Consolo, MD
Luigi Chiarini, MD
Copyright
2014
Uitgeverij
Springer Berlin Heidelberg
Boek
Complications in Endodontic Surgery

Print ISBN: 978-3-642-54217-6

Elektronisch ISBN: 978-3-642-54218-3

Copyright: 2014

DOI
https://doi.org/10.1007/978-3-642-54218-3_14